NGL Fine Chem Limited has announced a positive development in its credit rating assessment, with CRISIL Ratings revising the company's outlook while maintaining its existing rating levels. The company informed the stock exchanges about this rating revision on March 13, 2026.

Credit Rating Revision Details

CRISIL Ratings has made specific changes to NGL Fine-Chem Limited's credit assessment through their communication dated March 12, 2026. The rating agency has taken a more optimistic view of the company's financial prospects while maintaining confidence in its current rating levels.

Regulatory Compliance

The company has fulfilled its disclosure obligations under the Securities and Exchange Board of India regulations. NGL Fine-Chem Limited communicated this rating revision to both BSE Limited and the National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Rating Implications

The upgrade from 'Negative' to 'Stable' outlook on long-term bank loan facilities indicates CRISIL's improved confidence in the company's financial stability and business prospects. While the actual ratings remain unchanged, the outlook revision suggests reduced concerns about potential downgrades in the near term. The reaffirmation of both long-term and short-term ratings demonstrates maintained creditworthiness at current levels.

Corporate Communication

Company Secretary Shivam Gharat signed the official communication to the stock exchanges, ensuring proper documentation and regulatory compliance. The formal notification process was completed within the required timeframe, with the company requesting exchanges to take the information on record for investor awareness.

NGL Fine Chem has delivered exceptional financial results for Q3, showcasing remarkable growth across key performance metrics. The fine chemicals company reported a significant surge in profitability while maintaining strong revenue momentum during the quarter. The company has also released its investor presentation for Q3 & 9M FY26 under Regulation 30, providing comprehensive insights into its operational performance.

Outstanding Financial Performance

The company's Q3 consolidated results demonstrate outstanding performance with net profit experiencing extraordinary growth. Revenue figures also reflect robust business expansion, indicating strong operational execution and market demand for the company's products.

Operational Metrics and Business Mix

The company's operational performance shows strong diversification across segments and geographies. Animal API continues to dominate the revenue mix at 92% in Q3FY26, while the company has reduced its product concentration risk with top 3 products contributing 28% compared to 37% in the previous year.

Management Commentary on Performance

According to Managing Director Rahul Nachane, the company delivered strong performance across key financial and operational metrics in Q3FY26. The management highlighted that revenue growth was driven primarily by higher volumes across the product portfolio, while price realizations remained broadly stable. The profitability profile improved significantly, supported by slight easing in raw material costs and operational efficiencies implemented across manufacturing processes.

Expansion Plans and Capital Investment

The company's ongoing capital expenditure program remains on track, with Phase II commissioning scheduled for Q1FY27. Commercial production is expected to commence from the second half of FY27, with the total investment for the project revised to approximately ₹210 crore. The company has invested ₹156 crore till Q3FY26 in its greenfield expansion at Tarapur.

Market Position and Regulatory Progress

NGL Fine Chem continues to strengthen its position in the veterinary API segment with market leadership in key products and growing presence in regulated markets. The company has made substantial progress on regulatory filings with three CEPs approved, five additional filings submitted, five ASMF approvals received, and three VMF filings completed in the United States. The company maintains strong relationships with approximately 404 customers globally and supplies to 5 of the top 10 global animal healthcare companies.